Description

Product Description

Dasiglucagon is a synthetic human glucagon analog, engineered to mimic the biological activity of endogenous glucagon while offering enhanced stability for laboratory research applications. Glucagon, a key pancreatic hormone, plays a central role in glucose homeostasis by stimulating hepatic glucose production through glycogenolysis and gluconeogenesis. Dasiglucagon reproduces these effects in a controlled experimental context, allowing researchers to study hypoglycemia, glucose metabolism, and endocrine regulation with high precision.

In preclinical studies, Dasiglucagon effectively elevates plasma glucose in rodent and primate models, providing a reliable platform to evaluate glycemic responses, insulin-glucagon interplay, and counterregulatory mechanisms. The peptide is designed for high affinity binding to glucagon receptors (GCGR) in hepatic cells, triggering the cyclic AMP (cAMP) signaling cascade, activating protein kinase A (PKA), and promoting the mobilization of glucose from glycogen stores. This targeted mechanism allows investigators to study glucose kinetics, hormonal feedback loops, and pharmacodynamic effects in controlled laboratory environments.

Dasiglucagon’s GMP-grade production ensures reproducibility and batch consistency, critical for comparative studies and translational research. The lyophilized peptide maintains stability during storage, enabling researchers to conduct longitudinal experiments without compromising activity. It is suitable for in vitro, ex vivo, and in vivo studies, including cellular assays, isolated liver perfusion systems, and systemic hypoglycemia models.

The peptide is particularly valuable in research focused on hypoglycemia counterregulation, including investigations into the effects of insulin overdose, diabetes therapies, and hormonal feedback mechanisms. By selectively elevating glucose levels, Dasiglucagon allows laboratories to explore therapeutic interventions, receptor pharmacology, and signal transduction pathways in metabolic disorders.

Additionally, Dasiglucagon supports mechanistic studies on receptor-ligand interactions, downstream cAMP signaling, and cross-talk with other hormonal systems, such as insulin, GLP-1, and somatostatin. The peptide’s structure promotes high receptor selectivity and minimal off-target effects, which is essential for generating reproducible and interpretable results in preclinical research.

In summary, Dasiglucagon is an indispensable research tool for laboratories studying glucose homeostasis, hypoglycemia management, and endocrine physiology. Its combination of selective receptor activity, GMP-quality production, and robust pharmacodynamic effects provides a reliable foundation for translational metabolic research.

?? Disclaimer: For laboratory research use only. Not for human or veterinary use.

Product Specifications

Dasiglucagon’s specifications provide researchers with comprehensive experimental confidence, ensuring reproducible peptide quality for hypoglycemia studies, receptor pharmacology, and metabolic research. Its GMP-certified production reinforces its reliability for both bulk and small-scale laboratory applications.

Mechanism of Action & Research Applications

Dasiglucagon exerts its biological activity primarily through glucagon receptor activation (GCGR), a G protein-coupled receptor expressed predominantly in hepatic tissues. Upon binding to GCGR, Dasiglucagon triggers cAMP-dependent signaling, activating PKA, and stimulating glycogenolysis and gluconeogenesis, which increase plasma glucose levels. This action mimics the natural counterregulatory response to hypoglycemia, making it an ideal tool for laboratory research.

Mechanism Overview:

1. Receptor Binding and Selectivity
   Dasiglucagon exhibits high affinity for glucagon receptors, ensuring targeted hepatic glucose mobilization without significant interaction with other GPCRs. This specificity allows accurate modeling of glucagon-mediated pathways.

2. cAMP-PKA Signaling Activation
   The peptide induces cAMP accumulation, activating PKA. Activated PKA phosphorylates enzymes critical for glycogen breakdown, leading to rapid glucose release into circulation.

3. Gluconeogenesis and Glycogenolysis
   By activating both glycogenolysis and gluconeogenesis, Dasiglucagon provides sustained plasma glucose elevation, facilitating studies on glucose dynamics under hypoglycemic conditions.

4. Counterregulatory Feedback Studies
   Researchers can use Dasiglucagon to examine interactions between insulin and glucagon, elucidating feedback mechanisms in both normal and disease models, including diabetes and metabolic syndrome.

Research Applications:

• Hypoglycemia Modeling
  Dasiglucagon is used to simulate acute and chronic hypoglycemia, enabling pharmacological intervention studies and mechanistic investigations in rodent and primate models.

• Endocrine and Metabolic Research
  Researchers can study the effects of glucagon analogs on glucose homeostasis, insulin secretion, and pancreatic feedback mechanisms.

• Translational Research Potential
  The peptide facilitates preclinical evaluation of new therapies for hypoglycemia prevention and treatment, providing insights relevant to human physiology.

• In Vitro and Ex Vivo Studies
  Dasiglucagon can be applied to hepatocyte cultures or perfused liver models to study glucose mobilization kinetics, receptor pharmacodynamics, and downstream signaling.

• Combination Therapy Investigations
  The peptide serves as a tool for evaluating synergy with insulin, GLP-1 analogs, and other metabolic regulators, assisting in preclinical therapy optimization.

• Mechanistic Studies on Signal Transduction
  Researchers can explore cAMP-mediated pathways, receptor desensitization, and intracellular cross-talk, deepening understanding of glucagon biology.

• Pharmacokinetics and Dose-Response Studies
  Dasiglucagon enables precise measurement of dose-dependent glucose elevation, clearance rates, and systemic distribution, essential for translational modeling.

In summary, Dasiglucagon provides a robust, reproducible, and selective platform for investigating glucose regulation, hypoglycemia mechanisms, and endocrine physiology, supporting a wide array of laboratory research applications.

Side Effects (For Reference in Research Models)

Experimental observations in preclinical models indicate the following potential effects:

• Hyperglycemia
  Dose-dependent elevation of plasma glucose is expected; requires monitoring in experimental models.

• Hepatic Response
  Increased hepatic glucose production may transiently affect liver metabolism markers; useful for mechanistic studies.

• Cardiovascular Parameters
  Mild transient effects on heart rate or blood pressure may be observed in in vivo rodent models; monitor during systemic administration.

• Gastrointestinal Effects
  Some studies report mild nausea-like behaviors in animal models, reflecting glucagon’s effect on gastric motility.

• Pharmacokinetic Considerations
  Peptide stability is maintained in lyophilized form; avoid repeated freeze-thaw cycles to preserve experimental reproducibility.

• Experimental Model Observations
  Variability in glucose elevation may occur depending on species, model, and experimental design.

?? These effects are strictly for laboratory research reference. Dasiglucagon is not intended for human or veterinary use. Researchers should adhere to institutional safety protocols when handling the peptide.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Dasiglucagon

• Dasiglucagon CAS 1544300-84-6

• Human glucagon analog peptide

• Hypoglycemia research compound

• GMP supplier Dasiglucagon

• Plasma glucose modulator

• Endocrine research peptide

• Laboratory metabolic peptide

• Preclinical glucagon studies

• Wholesale and retail research peptide